Nevertheless, larger-scale research using more sophisticated methodologies is recommended to clarify the mechanisms behind Notch1 and CD10 expression in tumor progression and resistance, and to validate their potential as targeted therapies in CRC. This evidence concerns the gene MME and neoplasm.